Capricor Therapeutics Faces Securities Class Action Over Deramiocel Data

The complaint centers on allegations that Capricor violated the Securities Exchange Act by altering its statistical analysis plan for Deramiocel clinical data without prior FDA approval. According to the litigation, the company proceeded with a Biologics License Application resubmission despite the lack of a pre-specified plan agreement, creating a significant risk that the drug would fail to demonstrate sufficient effectiveness. These omissions allegedly rendered the company's public disclosures materially false throughout the class period, ultimately resulting in investor losses when the discrepancies emerged.

Shareholders do not need to be appointed as lead plaintiffs to participate in any potential recovery, though those interested in pursuing the case are encouraged to contact Brian Schall or David Schwartz at the Los Angeles-based firm. The lawsuit, which remains uncertified, serves as a mechanism for investors to seek damages for the decline in share value linked to the regulatory disclosures. Interested parties can reach the firm at 310-301-3335 or via their website to discuss legal options.